Interventional Cardiology
Advertisement
OCTIVUS shows PCI outcomes improve with EAPCI-defined stent optimization, regardless of imaging modality.
LuX-Valve offers a safe, effective option for severe TR patients at high surgical risk.
Dr. Salman Allana shares key insights on how operator volume impacts retrograde CTO PCI success and outcomes.
Experts call for better trials and teamwork to advance transcatheter valve treatment for heart failure-related valve disease.
CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes.
Delays in TAVI for acute decompensated aortic stenosis worsen outcomes.
First surgical removal of a Harmony valve due to endocarditis reveals complex challenges and implications.
NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes
The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis.
Dr. Amit Goyal of the CardioNerds analyzed the BHF PROTECT-TAVI trial.
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Patients between the ages of 50 and 70 years with a mechanical heart valve have better long-term survival.
Coronary Sinus Reducer Demonstrates Long-Term Efficacy in Refractory Angina: Insights from REDUCER-I
The observational REDUCER-I study aims to evaluate the real-world safety and effectiveness of the coronary sinus reducer.
Dr. Amit Goyal details a study which explored the role of coronary sinus reducer in Coronary microvascular dysfunction.
The possibility of DCBs to rescue side branches during provisional coronary bifurcation stenting is appealing.
Dr. Amit Goyal details the first-in-human study of the Magenta Elevate system.
Mayo Clinic researchers identified a new approach to treating infective endocarditis using a catheter-based method.
Results of the EARLY TAVR trial introduced a potential paradigm shift in managing asymptomatic high-gradient severe AS.
Two pivotal trials—EARLY TAVR and EVOLVED—were presented, each exploring early intervention in asymptomatic severe AS.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.